Side effect profile of interferon beta-1b in MS: Results of an open label trial

Neurology

Volumn 46, Issue 2, 1996, Pages 552-554

  Neilley, Laura K ^b   Goodin, Douglas S ^b   Goodkin, Donald E ^b   Hauser, Stephen L ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

BETA1 INTERFERON;

ADULT; ARTICLE; CLINICAL TRIAL; COHORT ANALYSIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DRUG EFFICACY; DRUG SAFETY; DRUG SELF ADMINISTRATION; FATIGUE; FEMALE; HEADACHE; HUMAN; IMPOTENCE; INFLUENZA; INSOMNIA; LEUKOPENIA; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; PRIORITY JOURNAL; RASH; TREATMENT OUTCOME;

EID: 0029897746     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/wnl.46.2.552     Document Type: Article

References (3)

1. IFNβ MS Study Group. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology 1993;43:655-661.
2. Paty DW Li DKB, UBC MS/MRI Study Group, IFNβ MS Study Group. Interferon beta-lb is effective in relapsing-remitting multiple sclerosis. II. MRI analysis results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology 1993;43:662-667.
3. Poser CM, Paty DW, Scheinberg L, et al. New diagnostic criteria for multiple sclerosis. Ann Neurol 1983;13:227-231.